Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 3

2(33.3%)

Phase 1

2(33.3%)

Phase 4

1(16.7%)

Phase 2

1(16.7%)

6Total

Phase 3(2)

Phase 1(2)

Phase 4(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT03049189Phase 3Active Not Recruiting

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

Role: collaborator

NCT06474806Phase 2Recruiting

Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer

Role: collaborator

NCT03362359Phase 1Completed

Ga-68-PSMA-11 in High-risk Prostate Cancer

Role: collaborator

NCT02656329Phase 3Terminated

International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device

Role: collaborator

NCT03556046Phase 1Completed

89Zr-girentuximab ) Dosimetry in CCRC Study - ZIR-DOSE

Role: collaborator

NCT00209417Phase 4Terminated

Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography

Role: collaborator

All 6 trials loaded